SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.
SIMLANDI is the first biosimilar approval under the strategic part… Read More
Canadian drug company JAMP Pharma has announced the launch of generic guanfacine for the treatment of attention deficit hyperactivity disorder (ADHD). The product is bioequivalent to Takeda… Read More
– Debut on Nasdaq follows completion of the company’s business combination with Oaktree Acquisition Corp. II, which included a fully committed and upsized $175 million PIPE ra… Read More